跳转至内容
Merck
所有图片(1)

Key Documents

AB1056F

Sigma-Aldrich

Anti-Adenovirus Antibody, FITC-conjugated

Chemicon®, from goat

登录查看公司和协议定价


About This Item

分類程式碼代碼:
12352203
eCl@ss:
32160702
NACRES:
NA.41

生物源

goat

品質等級

共軛

FITC conjugate

抗體表格

purified antibody

抗體產品種類

primary antibodies

無性繁殖

polyclonal

物種活性

human

製造商/商標名

Chemicon®

技術

immunofluorescence: suitable
immunohistochemistry: suitable

運輸包裝

wet ice

特異性

Adenovirus, hexon assembly. No cross-reactivity with Para 1-3, Influenza A & B or RSV. Non reactive with HEp-2 cells

免疫原

Hexon from adenovirus type 5.

應用

Anti-Adenovirus Antibody, FITC-conjugated is an antibody against Adenovirus for use in IF, IH.
Direct FA staining of target antigens in a permissive tissue culture system. Suggested dilution: 1:10-1:50. Acetone fixation of the antigen source is recommended prior to staining.

Optimal working dilutions must be determined by end user
Research Category
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral

外觀

IgG fraction conjugated to FITC. In PBS (0.01 M, pH 7.2) containing 10 mg/mL BSA and 0.1% sodium azide

儲存和穩定性

Maintain at 2-8°C for 3 months or at -20°C in undiluted aliquots for up to 12 months. Avoid repeated freeze/thaw cycles. Store under subdued light.

法律資訊

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

免責聲明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

未找到合适的产品?  

试试我们的产品选型工具.

儲存類別代碼

12 - Non Combustible Liquids

水污染物質分類(WGK)

WGK 2

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Comparison of adenoviruses from species B, C, E, and F after intravenous delivery.
Daniel Stone, Ying Liu, Zong-Yi Li, Sebastian Tuve, Robert Strauss, Andre Lieber
Molecular Therapy null
In situ adenovirus vaccination engages T effector cells against cancer.
Sebastian Tuve, Ying Liu, Khajornsak Tragoolpua, Jeffrey Daniel Jacobs et al.
Vaccine null
Yoshihiko Kakiuchi et al.
Molecular therapy : the journal of the American Society of Gene Therapy, 29(10), 2920-2930 (2021-05-24)
Extracellular vesicles (EVs) play important roles in various intercellular communication processes. The abscopal effect is an interesting phenomenon in cancer treatment, in which immune activation is generally considered a main factor. We previously developed a telomerase-specific oncolytic adenovirus, Telomelysin (OBP-301)
Sacha Robert et al.
Viruses, 16(4) (2024-04-27)
Adjuvant systemic therapies effectively reduce the risk of breast cancer recurrence and metastasis, but therapy resistance can develop in some patients due to breast cancer stem cells (BCSCs). Oncolytic adenovirus (OAd) represents a promising therapeutic approach as it can specifically
Shuhei Shinoda et al.
Cancer science, 114(9), 3759-3769 (2023-07-13)
Past clinical trials of adjuvant therapy combined with interferon (IFN) alpha, fluorouracil, cisplatin, and radiation improved the 5-year survival rate of pancreatic ductal adenocarcinoma (PDAC). However, these trials also revealed the disadvantages of the systemic toxicity of IFN and insufficient

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门